葡萄膜黑色素瘤生存预后相关lncRNA的初步筛选及相关性分析

doi:10.3760/cma.j.cn115909-20210513-00193

摘要
图/表
参考文献(32)
相关文章 (1)

全文: PDF 1922KB HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

文章导读

摘要目的：通过构建lncRNA-miRNA-mRNA的内源竞争RNA（ceRNA）网络，筛选与葡萄膜黑色素瘤（UM）生存预后相关的长链非编码RNA（lncRNA），并进行相关性分析。方法：以生物信息学为手段，通过疾病预后相关分析，LncRNA亚细胞定位检索，从肿瘤基因组图谱数据库中筛选lncRNA表达数据集。通过mircode数据库和targetscan 数据库找到lncRNAs对应的靶microRNA（miRNA），Venn 分析筛选出共同的与UM预后相关的miRNA。在多个数据库中同时检索，筛选出共同的miRNAmRNA 。通过KEGG富集与lncRNA-miRNA-mRNA网络可视化，最终确定出与UM生存预后相关的候选lncRNA。结果：在对lncRNA的下游靶miRNA及功能基因的预测中，鉴定出了630 对候选miRNAmRNA 。通过ceRNA调控基因表达的机制，筛选出了9 个可能发挥ceRNA功能的lncRNA。KEGG分析得到lncRNA的下游调控基因主要富集在参与肿瘤病理进程的信号通路中。SHNG6可能通过调控 has-miR-214-5p、has-miR-214-3p、has-miR-let-7b-5p、has-miR-let-7c-3p等miRNAs，调节下游的功能基因BAX、IGF1R、KRAS、PIK3R1、PDGFD等。结论：lncRNAs通过ceRNAs机制，调控一系列参与肿瘤发生发展的致癌基因的表达，影响UM的预后及治疗，SHNG6、LINC01278 等lncRNAs可能在其发生发展、迁移及侵袭等方面扮演着重要角色。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	尚会平
	林祥祥.

关键词 ：葡萄膜黑色素瘤, 长链非编码RNA, 内源竞争RNA

Abstract：Objective: To construct a competing endogenous RNA (ceRNA) network of lncRNA-miRNA-mRNA, and to screen the long non-coding RNA (lncRNA) associated with the survival prognosis of uveal melanoma (UM). Methods: In this study, the expression data set of lncRNA was screened from the Tumor Genome Atlas Database through disease prognosis correlation analysis and a subcellular localization search of lncRNA using bioinformatics methods. Target microRNAs (miRNAs) corresponding to lncRNAs were found by the mircode database, targetscan database, and common miRNAs associated with UM prognosis were screened out by Venn analysis. The common miRNA-mRNA was screened from multiple databases simultaneously. Through KEGG enrichment and lncRNA-miRNA-mRNA network visualization, candidate lncRNAs related to the survival prognosis of UM were finally identified. Results: In the prediction of downstream target miRNAs and the functional genes of lncRNAs, 630 pairs of candidate miRNA-mRNA were identified. Based on the mechanism of gene expression regulation by ceRNAs, 9 lncRNAs that might play the role of ceRNAs were screened out. KEGG analysis showed that the downstream regulatory genes of lncRNAs were mainly enriched in the signaling pathways involved in the pathological process of tumors. SHNG6 may regulate miRNAs such as has-miR-214-5p, has-miR-214-3p, has-miR-let-7b-5p, and has-miR-let-7c-3p, the regulators of downstream functional genes BAX, IGF1R, KRAS, PIK3R1, PDGFD and so on. Conclusions: Through the mechanism of ceRNAs, lncRNAs regulate the expression of a series of oncogenes involved in tumor genesis and development, and affect the prognosis and treatment of UM. lncRNAs such as SHNG6 and LINC01278 may play an important role in its occurrence, development, migration and invasion.

Key words： uveal melanoma long non-coding RNA competing endogenous RNA

收稿日期: 2021-05-13

PACS:

基金资助:

通讯作者: 林祥祥（ORCID：0000-0003-2912-0877），Email：xiangxianglin003@163.com

引用本文:

尚会平，林祥祥.. 葡萄膜黑色素瘤生存预后相关lncRNA的初步筛选及相关性分析[J]. 中华眼视光学与视觉科学杂志, 2022, 24(3): 208-215. Huiping Shang1, Xiangxiang Lin2. Preliminary Screening and Analysis of Survival Prognostic lncRNA in Uveal Melanoma. Chinese Journal of Optometry Ophthalmology and Visual science, 2022, 24(3): 208-215. DOI: 10.3760/cma.j.cn115909-20210513-00193

链接本文:

https://www.cjoovs.com/CN/10.3760/cma.j.cn115909-20210513-00193 或 https://www.cjoovs.com/CN/Y2022/V24/I3/208

[1]	Smit KN, Jager MJ, de Klein A, et al. Uveal melanoma: towards a molecular understanding. Prog Retin Eye Res, 2020, 75:100800. DOI: 10.1016/j.preteyeres.2019.100800.
[2]	中国医药教育协会眼科专业委员会, 中华医学会眼科学分会眼整形眼眶病学组,中国抗癌协会眼肿瘤专业委员会.中国葡萄膜黑色素瘤诊疗专家共识(2021年). 中华眼科杂志, 2021, 57(12): 886-897. DOI: 10.3760/cma.j.cn112142-20210926-00452.
[3]	Ghazawi FM, Darwich R, Le M,et al. Uveal melanoma incidence trends in Canada: a national comprehensive population-based study. Br J Ophthalmol, 2019, 103(12): 1872- 1876. DOI: 10.1136/bjophthalmol-2018-312966.
[4]	Xu Y, Lou L, Wang Y, et al.Epidemiological Study of Uveal Melanoma from US Surveillance, Epidemiology, and End Results Program (2010-2015). J Ophthalmol, 2020, 2020:3614039. DOI: 10.1155/2020/3614039.
[5]	Souto EB, Zielinska A, Luis M, et al. Uveal melanoma: physiopathology and new in situ-specific therapies. Cancer Chemother Pharmacol, 2019, 84(1): 15-32. DOI: 10.1007/ s00280-019-03860-z.
[6]	Singh MK, Singh L, Chosdol K, et al.Differential expression of p52 and RelB proteins in the metastatic and non-metastatic groups of uveal melanoma with patient outcome. J Cancer Res Clin Oncol, 2019, 145(12): 2969-2982. DOI: 10.1007/s00432- 019-03052-5.
[7]	Bagger M, Smidt-Nielsen I, Andersen MK, et al.Long-Term Metastatic Risk after Biopsy of Posterior Uveal Melanoma. Ophthalmology, 2018, 125(12): 1969-1976. DOI: 10.1016/ j.ophtha.2018.03.047.
[8]	Field MG, Decatur CL, Kurtenbach S, et al. PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma. Clin Cancer Res, 2016, 22(5): 1234-1242. DOI: 10.1158/1078-0432. Ccr-15-2071.
[9]	Koopmans AE, Vaarwater J, Paridaens D, et al.Patient survival in uveal melanoma is not affected by oncogenic mutations in GNAQ and GNA11. Br J Cancer, 2013, 109(2): 493-496. DOI: 10.1038/bjc.2013.299.
[10]	Chattopadhyay C, Kim DW, Gombos DS, et al. Uveal melanoma: from diagnosis to treatment and the science in between.Cancer, 2016, 122(15): 2299-2312. DOI: 10.1002/cncr.29727.
[11]	Wan Q, Tang J, Han Y, et al. Co-expression modules construction by WGCNA and identify potential prognostic markers of uveal melanoma. Exp Eye Res, 2018, 166:13-20. DOI: 10.1016/ j.exer.2017.10.007.
[12]	赵云萍, 金珊珊, 刘琦, 等. DZNep靶向EZH2抑制葡萄膜黑色素瘤细胞增殖.中华眼视光学与视觉科学杂志. 2020, 22(7): 492-499. DOI: 10.3760/cma.j.cn115909-20190426-00124.
[13]	Johansson P, Aoude LG, Wadt K, et al.Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4.Oncotarget, 2016, 7(4): 4624-4631. DOI: 10.18632/oncotarget.6614.
[14]	Moore AR, Ceraudo E, Sher JJ, et al. Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma. Nat Genet, 2016, 48(6): 675-680. DOI: 10.1038/ ng.3549.
[15]	Turunen JA, Markkinen S, Wilska R, et al. BAP1 Germline Mutations in Finnish Patients with Uveal Melanoma.Ophthalmology, 2016, 123(5): 1112-1117. DOI: 10.1016/ j.ophtha.2016.01.008.
[16]	Cebulla CM, Binkley EM, Pilarski R, et al. Analysis of BAP1 Germline Gene Mutation in Young Uveal Melanoma Patients.Ophthalmic Genet, 2015, 36(2): 126-131. DOI: 10.3109/13816810.2015.1010734.
[17]	Maerker DA, Zeschnigk M, Nelles J, et al. BAP1 germline mutation in two first grade family members with uveal melanoma.Br J Ophthalmol, 2014, 98(2): 224-227. DOI: 10.1136/bjophthalmol-2013-303814.
[18]	Coupland SE, Lake SL, Zeschnigk M, et al. Molecular pathology of uveal melanoma. Eye (Lond), 2013, 27(2): 230- 242. DOI: 10.1038/eye.2012.255.
[19]	Ewens KG, Kanetsky PA, Richards-Yutz J, et al. Chromosome 3 status combined with BAP1 and EIF1AX mutation profiles are associated with metastasis in uveal melanoma.Invest Ophthalmol Vis Sci, 2014, 55(8): 5160-5167. DOI: 10.1167/ iovs.14-14550.
[20]	李洋, 冯宇, 刘月明, 等.BAP1、 FOXO3 和 ITPR2 基因表达变化与葡萄膜黑色素瘤转移和预后关联分析. 中华实验眼科杂志. 2021, 39(8): 700-707. DOI: 10.3760/cma. j.cn115989-20200714-00495.
[21]	Joshi MRajender S. Long non-coding RNAs (lncRNAs) in spermatogenesis and male infertility. Reprod Biol Endocrinol, 2020, 18(1): 103. DOI: 10.1186/s12958-020-00660-6.
[22]	Panni S, Lovering RC, Porras P, et al. Non-coding RNA regulatory networks. Biochim Biophys Acta Gene Regul Mech, 2020, 1863(6): 194417. DOI: 10.1016/j.bbagrm.2019.194417.
[23]	Yu X, Zheng H, Tse G, et al.Long non-coding RNAs in melanoma. Cell Prolif, 2018, 51(4): e12457. DOI: 10.1111/cpr.12457.
[24]	Huarte M. The emerging role of lncRNAs in cancer. Nat Med, 2015, 21(11): 1253-1261. DOI: 10.1038/nm.3981.
[25]	Li MX, Wang HY, Yuan CH, et al.KLHDC7B-DT aggravates pancreatic ductal adenocarcinoma development via inducing cross-talk between cancer cells and macrophages. Clin Sci (Lond), 2021, 135(4): 629-649. DOI: 10.1042/cs20201259.
[26]	Huang GZ, Wu QQ, Zheng ZN, et al. Identification of Candidate Biomarkers and Analysis of Prognostic Values in Oral Squamous Cell Carcinoma. Front Oncol, 2019, 9:1054. DOI: 10.3389/ fonc.2019.01054.
[27]	Zheng J, Huang X, Tan W, et al.Pancreatic cancer risk variant in LINC00673 creates a miR-1231 binding site and interferes with PTPN11 degradation.Nat Genet, 2016, 48(7): 747-757. DOI: 10.1038/ng.3568.
[28]	Yu T, Zhao Y, Hu Z, et al. MetaLnc9 Facilitates Lung Cancer Metastasis via a PGK1-Activated AKT/mTOR Pathway. Cancer Res, 2017, 77(21): 5782-5794. DOI: 10.1158/0008-5472.Can- 17-0671.
[29]	Fan X, Song J, Zhao Z, et al. Piplartine suppresses proliferation and invasion of hepatocellular carcinoma by LINC01391- modulated Wnt/β-catenin pathway inactivation through ICAT. Cancer Lett, 2019, 460:119-127. DOI: 10.1016/ j.canlet.2019.06.008.
[30]	Xu M, Chen X, Lin K, et al. lncRNA SNHG6 regulates EZH2 expression by sponging miR-26a/b and miR-214 in colorectal cancer. J Hematol Oncol, 2019, 12(1): 3. DOI: 10.1186/s13045- 018-0690-5.
[31]	Zhang Y, An J, Pei Y. LncRNA SNHG6 promotes LMO3 expression by sponging miR-543 in glioma. Mol Cell Biochem, 2020, 472(1-2): 9-17. DOI: 10.1007/s11010-020-03772-0.
[32]	Chen S, Xie C, Hu X. lncRNA SNHG6 functions as a ceRNA to up-regulate c-Myc expression via sponging let-7c-5p in hepatocellular carcinoma.Biochem Biophys Res Commun, 2019, 519(4): 901-908. DOI: 10.1016/j.bbrc.2019.09.091.，